Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21245096rdf:typepubmed:Citationlld:pubmed
pubmed-article:21245096lifeskim:mentionsumls-concept:C0079427lld:lifeskim
pubmed-article:21245096lifeskim:mentionsumls-concept:C0345967lld:lifeskim
pubmed-article:21245096lifeskim:mentionsumls-concept:C1334331lld:lifeskim
pubmed-article:21245096pubmed:issue3lld:pubmed
pubmed-article:21245096pubmed:dateCreated2011-2-2lld:pubmed
pubmed-article:21245096pubmed:abstractTextMalignant mesothelioma (MM) is an aggressive neoplasm associated with asbestos exposure. We carried out genome-wide array-based comparative genomic hybridization analysis with 14 MM cell lines. Three cell lines showed overlapping homozygous deletion at chromosome 13q12, which harbored the LATS2 (large tumor suppressor homolog 2) gene. With 6 other MM cell lines and 25 MM tumors, we found 10 inactivating homozygous deletions or mutations of LATS2 among 45 MMs. LATS2 encodes a serine/threonine kinase, a component of the Hippo tumor-suppressive signaling pathway, and we transduced LATS2 in MM cells with its mutation. Transduction of LATS2 inactivated oncoprotein YAP, a transcriptional coactivator, via phosphorylation, and inhibited MM cell growth. We also analyzed LATS2 immunohistochemically and found that 13 of 45 MM tumors had low expression of LATS2. Because NF2 is genetically mutated in 40% to 50% of MM, our data indicate that Hippo pathway dysregulation is frequent in MM cells with inactivation of LATS2 or an upstream regulator of this pathway, Merlin, which is encoded by NF2. Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation.lld:pubmed
pubmed-article:21245096pubmed:languageenglld:pubmed
pubmed-article:21245096pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:citationSubsetIMlld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21245096pubmed:statusMEDLINElld:pubmed
pubmed-article:21245096pubmed:monthFeblld:pubmed
pubmed-article:21245096pubmed:issn1538-7445lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:ToyokuniShiny...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:OsadaHirotaka...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:MurakamiHidek...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:FujiiMakikoMlld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:SekidoYoshita...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:HidaToyoakiTlld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:HorioYoshitsu...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:KondoYutakaYlld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:AkatsukaShiny...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:MizunoTetsuya...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:FukuiTakayuki...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:TaniguchiTets...lld:pubmed
pubmed-article:21245096pubmed:authorpubmed-author:IshiguroFutos...lld:pubmed
pubmed-article:21245096pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21245096pubmed:day1lld:pubmed
pubmed-article:21245096pubmed:volume71lld:pubmed
pubmed-article:21245096pubmed:ownerNLMlld:pubmed
pubmed-article:21245096pubmed:authorsCompleteYlld:pubmed
pubmed-article:21245096pubmed:pagination873-83lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:meshHeadingpubmed-meshheading:21245096...lld:pubmed
pubmed-article:21245096pubmed:year2011lld:pubmed
pubmed-article:21245096pubmed:articleTitleLATS2 is a tumor suppressor gene of malignant mesothelioma.lld:pubmed
pubmed-article:21245096pubmed:affiliationDivision of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan.lld:pubmed
pubmed-article:21245096pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21245096pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:26524entrezgene:pubmedpubmed-article:21245096lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21245096lld:entrezgene